# Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.

> **NCT03234907** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 215 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Vedolizumab IV
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03234907
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-03
- **Primary completion:** 2020-08-14
- **Final completion:** 2020-08-14
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03234907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03234907, "Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03234907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*